```markdown
October/2019

सत्यमेव जयते
Department of Health Research
Ministry of Health and Family Welfare, Government of India

OF MEDICAL RESEARCH
NEW DELHI
icma
INDIAN COUNCIL OF
MEDICAL RESEARCH
Serving the nation since 1911

# Standard Treatment Workflow (STW) for the Management of
DEPRESSION
ICD10-F45

## CORE SYMPTOMS

1. Depressed
mood
2. Loss of
interest
and
enjoyment
3. Easy
fatigability/
diminished
activity

## CLINICAL ASSESSMENT

*   Cognition
    *   Hopelessness (about future)
    *   Helplessness (about others)
    *   Worthlessness (about self)
*   Assessment of Suicide Risk
    *   Suicidal thoughts
    *   Suicidal idea
    *   Suicidal intent
    *   Immediate risk for attempt

Assessment
of
Depressive
Cognition

Assess
friend
and
family
support

## ADDITIONAL SYMPTOMS

*   Reduced concentration and attention
*   Reduced self-esteem and self-confidence
*   Ideas of guilt and unworthiness
*   Bleak and pessimistic views of the future
*   Ideas or acts of self-harm or suicide
*   Disturbed sleep
*   Diminished appetite

To make a diagnosis of depression, symptoms
must present for at least 2 weeks.

| Severity of depression | Core symptoms | Additional symptoms |
|:-----------------------|:---------------|:----------------------|
| Mild depression         | 2              | 2 or more             |
| Moderate depression     | 2              | 3 or more             |
| Severe depression       | 3              | 4 or more             |

*   Haemogram

## INVESTIGATION

*   Thyroid function tests
*   Electro Cardiogram
*   Electrolytes (Sodium)
*   Rule out secondary medical cause of depression like Hypothyroidism
*   Rule out use of anticancer drugs (Cyclophoshamide) / anti retroviral drugs (Efavirenz, Zidovudine)/ Antibiotics (Dapsone, Ethambutol)/ Anabolic Steroids/ Propanolol
*   Rule out associated comorbid medical condition - Diabetes, Stroke, Epilepsy, Cancer, Coronary Artery Disease and Auto Immune disorder

CLINICAL
DIAGNOSIS OF
DEPRESSION

## AT PRIMARY CARE

### MILD DEPRESSION

*   Advise Behavioral Activation to patients
*   Practicing activity monitoring - write down your activities / rate your depression / schedule activities
that make you feel good / make a to do list/ set clear and specific goals
*   Focusing on your value categories - make time for your family / friends / set clear goals at work / contribute to community
*   Handling daily task monitor sleep/diet and practice good personal hygiene
*   Supportive psychotherapy / Brief Counselling
*   Validate the problems and ensure frequent follow-up
*   If no improvement in 4 to 6 weeks, consider pharmacotherapy

### REFERRAL TO SECONDARY CARE

*   Difficulty in making diagnosis
*   No improvement after 4 to 6
weeks of treatment with first
line medications
*   Depression in special
population: Elderly /
Pregnancy / Lactation /
Children / Adolescents
*   Comorbid medical illness /
Substance use
*   Suicidal risk assessment

### REFERRAL TO TERTIARY CARE

*   No improvement in 2nd
line treatment
*   Immediate risk for
suicidal attempt /
thought
*   Needing intense
counselling/
psychotherapy
*   Co Morbid Substance -
Cannabis / Poly
substance

## BROAD MANAGEMENT PLANS

*   Selective Serotonin Reuptake Inhibiters (**SSRI**) are
usually first choice (watch for GI bleed and drug interaction)
*   Improvement starts in in 2nd week and expect
adequate response by 6 weeks
*   Duration of treatment typically lasts 6-9 months
and Gradual tapering of medication advised for first episode
*   Restart SSRI, In case of resurgence and recurrence
of depressive symptoms
*   Observe for switch / activation with Antidepressants
*   Watch for risk of overdose with TCA (Amitriptyline /
Imipramine) and Mirtazapine

### SPECIAL POPULATION

*   Pregnancy / Lactation period -
Pre Conception counselling and
preferred drug is
    *   Tab. Sertraline 50 mg use
    lowest possible dose
*   Elderly -
    *   Tab. Escitalopram 10-20 mg or
    Tab. Sertraline 100 mg
    (monitor for hyponatremia)
*   Avoid TCAs like Amitriptyline /
Imipramine in Elderly (due to
anticholinergic side effects)
*   Adolescents- Cap. Fluoxetine
20-40 mg/day (observe for
switch / activation/ suicidality)

## MODERATE/SEVERE DEPRESSION

*   Tab Escitalopram 10 mg-20 mg/day or
Cap. Fluoxetine 20mg -40mg/day
*   Tab. Clonazepam 0.25mg - 0.5mg/day
for sleep disturbance / anxiety
symptoms and consider taper and stop
after 2 weeks.
*   If patient responds to SSRI in 2 to 4
weeks, then continue treatment for 6 to
9 months and taper and stop

## AT SECONDARY CARE

*   Confirm Diagnosis and Suicide risk
assessment
*   Assess for other Medical
Comorbidities
*   Investigations - Haemoglobin, Thyroid
Function Test, Electrocardiogram
*   Non Responder - Switch over to **SNRI**
(Venlafaxine 75 - 150 mg, Mirtazapine
30 mg) or **TCA** (Amitriptyline 75 -
225mg/Imipramine 75-225mg)
*   Cognitive Behavioral Therapy /
Problem Solving Therapy
*   Add on Yoga Therapy / Meditation

### AT TERTIARY CARE

*   Reconfirm Diagnosis
*   Assess other psychiatric comorbidities
*   Partial Responder - Optimise the SNRI /TCA or Augment
with Tab. Lithium 300 to 600mg /per day or Tab. Thyroxine
25-50 ug per day.
*   Non Responder - Add Tab. Sertraline 100mg or
Tab. Bupropion 300mg to existing Venlafaxine 150mg/
Tab. Mirtazapine 30mg / Amitriptyline 225mg /
Imipramine 225mg.
*   Add on Electro Convulsive Therapy for Catatonia /
Suicidality
*   Add on Cognitive Behavioural Therapy/ Inter Personal
Therapy / Problem Solving Therapy
*   Add on low dose antipsychotic treatment (Risperidone 2 -4
mg / Tab. Olanzapine 5 - 10 mg) for psychotic symptoms

## REFERENCES

*   Gautam S et al., Clinical Practice Guidelines for the management of Depression. Indian J Psychiatry. 2017;59 (Suppl 1):S34-S50.
*   Avasthi A, Grover S. Clinical practice guidelines for management of depression in elderly. Indian J Psychiatry 2018;60, Suppl S3:341-62
*   Sarkar S, Grover S. A systematic review and meta-analysis of trials of antidepressants in India for treatment of depression. Indian J Psychiatry. 2014;56:29-38
*   National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical Guideline 23. London: NICE, 2004.
*   mhGAP Intervention Guide - Version 2.0 for mental, neurological and substance use disorders in non-specialized health settings. World Health Organisation, 2016

## KEEP A HIGH THRESHOLD FOR INVASIVE PROCEDURES

This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit our web portal (stw.icmr.org.in) for more information.

Indian Council of Medical Research and Department of Health Research, Ministry of Health & Family Welfare, Government of India.
```